U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07775924) titled 'A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus' on Aug. 17.
Brief Summary: This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
Study Start Date: Sept. 10
Study Type: INTERVENTIONAL
Condition:
Cutaneous Lichen Planus
Intervention:
DRUG: Placebo
Matching placebo
DRUG: GIA632
GIA632 administered according to the assigned study treatment regimen.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Service...